Millions of older adults take glucosamine every day to help ease joint pain and support mobility. But new research suggests this popular supplement may have an unexpected downside for people at risk of Alzheimer's disease.
Scientists at the University of Florida have found that glucosamine use was associated with a greater likelihood of progressing from mild cognitive impairment (MCI) to Alzheimer's disease and other forms of dementia. The findings, published in Nature Metabolism, are raising important questions about how certain supplements may affect brain health.
What the Study Found
Researchers analyzed more than a decade of electronic health records from patients diagnosed with either mild cognitive impairment or Alzheimer's disease and related dementias (ADRD). Using artificial intelligence, they searched for patterns that might reveal factors influencing disease progression.
The team discovered that approximately 8% of patients in both groups reported taking glucosamine supplements. After adjusting for age, sex, and other demographic factors, they found that glucosamine users with mild cognitive impairment were 25% more likely to progress to dementia than non-users.
Among patients already living with dementia, glucosamine use was also associated with a 25% higher risk of death during the study period.
While these findings do not prove that glucosamine causes Alzheimer's disease or dementia, they do suggest a potential link that deserves further investigation.
Why Researchers Are Concerned
The study focused on a metabolic process known as protein sugar-tagging. This process helps proteins function properly by attaching sugar molecules to them. However, researchers found evidence that this system may become overactive in Alzheimer's disease.
Glucosamine, a sugar-related compound, can cross the blood-brain barrier and influence these biological pathways. The researchers believe excessive activity in this sugar-tagging process may contribute to the progression of Alzheimer's disease.
Using advanced imaging technology, the team examined brain tissue from both Alzheimer's patients and laboratory mice. They found increased levels of sugar-tagged proteins in diseased brains compared to healthy brains.
According to the study's lead author “This technology allows us to examine thousands and thousands of molecules created when the body breaks down food or drugs and to uncover intricate pathways that otherwise would stay hidden."
Evidence from Animal Studies
To better understand what was happening, the researchers tested glucosamine in genetically modified mice that develop Alzheimer's-like symptoms.
The results were striking. Mice given glucosamine showed increased sugar-tagging activity in brain cells and experienced worsening social memory, a type of memory involved in recognizing familiar individuals.
When scientists blocked the sugar-tagging process, memory performance improved, suggesting that this pathway may play a direct role in cognitive decline.
A New Target for Alzheimer's Research
The findings add to a growing body of evidence that metabolic dysfunction may be a major driver of Alzheimer's disease.
Most current Alzheimer's treatments focus on reducing amyloid plaques and tau tangles in the brain. However, researchers believe targeting metabolic pathways could become another important strategy for slowing disease progression.
"This study suggests altered metabolism may be a significant contributor to Alzheimer's progression," the researchers noted, highlighting the need for additional investigation into potential treatments that address these underlying metabolic changes.
Should You Stop Taking Glucosamine?
Not necessarily.
Experts stress that this study found an association, not proof that glucosamine directly causes dementia or accelerates Alzheimer's disease. Clinical trials in humans will be needed before any firm recommendations can be made.
However, because glucosamine is widely used by older adults—the same population most at risk for dementia—the findings are significant and warrant further research.
Senior author Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF’s McKnight Brain Institute says:
“A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse.”
If you have concerns about glucosamine or any dietary supplement, it's best to discuss them with your healthcare provider before making changes to your routine.
The Bottom Line
A new University of Florida study suggests that glucosamine, a common supplement used for joint health, may be linked to a higher risk of progression from mild cognitive impairment to dementia. While more research is needed to determine whether the supplement plays a direct role, the findings highlight an important new area of Alzheimer's research and underscore the complex relationship between metabolism and brain health.
Comments